Bezuclastinib sunitinib combo shows promise in second-line GIST treatment
Published on 30 May 2026
Dr Andrew Wagner talks to ecancer at ASCO 2026 about results from a global randomised trial evaluating sunitinib plus bevacizumab for second-line treatment of gastrointestinal stromal tumour (GIST).
The combination therapy improved progression-free survival and response rates compared with sunitinib alone, leading Dr Wagner to speculate it could become a new standard of care, pending regulatory approval.